-
公开(公告)号：KR1020040076735A
公开(公告)日：2004-09-03
申请号：KR1020030012079
申请日：2003-02-26
Applicant: 대한민국 (식품의약품안전처장)
IPC: A01K67/027
CPC classification number: A01K67/0276 , A01K2227/105 , C12N15/09
Abstract: PURPOSE: A transgenic dementia mouse expressing a mutant PS2 gene and a manufacturing process thereof are provided to be utilized usefully in treating a dementia disease or improving an early diagnosis process of the disease. CONSTITUTION: The manufacturing process of the transgenic dementia mouse expressing a mutant PS2 gene comprises the steps of: preparing a hybrid gene NSE/hPS2m by connecting to a promoter of a neuron-specific enolase gene to a mutant PS2 dementia gene derived from a human; micro-injecting the hybrid gene into a fertilized egg of a mouse; and implanting the fertilized egg into an oviduct of a surrogate mother mouse.
Abstract translation: 目的：提供一种表达突变型PS2基因的转基因痴呆小鼠及其制备方法，可用于治疗痴呆疾病或改善疾病的早期诊断过程。 构成：表达突变型PS2基因的转基因痴呆小鼠的制造方法包括以下步骤：通过将神经元特异性烯醇化酶基因的启动子连接到源自人的突变型PS2痴呆基因来制备杂合基因NSE / hPS2m; 将杂交基因微注射到小鼠的受精卵中; 并将受精卵植入代孕母鼠的输卵管中。
-
公开(公告)号：KR101131597B1
公开(公告)日：2012-05-17
申请号：KR1020090019671
申请日：2009-03-09
Applicant: 대한민국 (식품의약품안전처장) , 한국생명공학연구원 , 서울대학교산학협력단
IPC: G01N33/15 , C12N15/33 , A01K67/027
Abstract: 본 발명은 사람의 B형 간염바이러스 X유전자로 형질전환된 동종접합 마우스에 목적하는 약물을 투여하고, 시험약물을 투여하지 않은 마우스와 비교하여 시험약물의 발암성 여부를 확인하는 단계를 포함하는 발암성을 나타내는 약물을 판별하는 방법에 관한 것이다. 본 발명의 발암성을 나타내는 약물을 판별하는 방법은 (i) 사람의 B형 간염 바이러스 X 유전자로 형질전환된 동형접합(homozygous) HBx
Ob 마우스(KCTC 11068BP)에 시험약물을 투여하고 사육하는 단계; 및, (ii) 상기 마우스로부터 간을 적출하여, 적출된 간 조직의 병변을 관찰한 다음, 시험약물을 투여하지 않은 HBx
Ob 마우스의 그것들과 비교하여, 시험약물의 발암성 여부를 확인하는 단계를 포함한다. 본 발명의 방법을 이용하면, 목적하는 약물의 간 발암성을 단시간에 효과적으로 예측하여, 신약의 발암성 시험에 소요되는 비용과 시간을 절감할 수 있으므로, 보다 경제적이고 효과적인 의약의 개발에 널리 이바지 할 수 있을 것이다.
B형 간염 바이러스 X 유전자, 시험약물, 발암성-
公开(公告)号：KR1020100101272A
公开(公告)日：2010-09-17
申请号：KR1020090019671
申请日：2009-03-09
Applicant: 대한민국 (식품의약품안전처장) , 한국생명공학연구원 , 서울대학교산학협력단
IPC: G01N33/15 , C12N15/33 , A01K67/027
Abstract: PURPOSE: A method for determining a drug with carcinogenicity is provided to effectively predict carcinogenicity in a short time and to reduce time and cost for testing carcinogenicity of a novel drug. CONSTITUTION: A method for determining a drug with carcinogenicity comprises: a step of administering test drug to homogygous HBx^Ob mouse(KCTC 11068BP) which is transformed with a hepatitis virus X gene and raising; a step of extracting the liver from the mouse and observing lesion of extracted liver; a step of comparing the liver with a liver of HBx^Ob mouse in which test drug is not administered; a step of checking the carcinogenicity of the test drug. The HBx^Ob mouse is raised at least 26 weeks. The lesion of the liver is hepatic alternative foci. The hepatic alternative foci are basophilic foci, eosinophilic foci, clear cell foci, amphophilic foci, vacuolated foci or mixed foci.
Abstract translation: 目的：提供一种确定具有致癌性的药物的方法，以在短时间内有效预测致癌性，并减少测试新药的致癌性的时间和成本。 构成：用于确定具有致癌性的药物的方法包括：将试验药物施用于用肝炎病毒X基因转化并升高的同型HBx ^ Ob小鼠（KCTC 11068BP）的步骤; 从小鼠中提取肝脏并观察肝脏病变的一个步骤; 将肝脏与未施用测试药物的HBx ^ Ob小鼠的肝脏进行比较的步骤; 检查试验药物的致癌性的步骤。 HBx ^ Ob小鼠至少培养26周。 肝脏的病变是肝替代灶。 肝替代灶是嗜碱性灶，嗜酸粒细胞病灶，透明细胞病灶，两性灶，空泡化灶或混合灶。
-
公开(公告)号：KR1020040110730A
公开(公告)日：2004-12-31
申请号：KR1020030040171
申请日：2003-06-20
Applicant: 대한민국 (식품의약품안전처장)
IPC: A01K67/027
CPC classification number: A01K67/0276 , A01K2227/105 , C12N15/63
Abstract: PURPOSE: A transgenic Alzheimer's mice expressing APPsw gene and a preparation method thereof are provided to show almost perfect Alzheimer symptoms and to be used in developing an Alzheimer treatment and an early diagnosis manner. CONSTITUTION: The preparation method of the transgenic Alzheimer's mice expressing APPsw(Amyloid precursor protein swedish) gene comprises the steps of: preparing a recombinant fusion gene by connecting an APPsw gene to a promoter of a NSE(Neur on-Specific Enolase) gene; microinjecting the recombinant fusion gene into a fertilized egg of a mouse; and breeding by nidating the fertilized egg into an abduct of a surrogate mother mouse.
Abstract translation: 目的：提供表达APPsw基因的转基因阿尔茨海默氏小鼠及其制备方法，以显示几乎完美的阿尔茨海默症状，并用于开发阿尔茨海默病和早期诊断。 构成：表达APPsw（淀粉样前体蛋白质瑞典）基因的转基因阿尔茨海默氏小鼠的制备方法包括以下步骤：通过将APPsw基因连接到NSE（Neur on-Specific Enolase）基因的启动子来制备重组融合基因; 将重组融合基因显微注射入小鼠的受精卵中; 并通过将受精卵覆盖到替代母亲小鼠的绑架中进行繁殖。
-
-
-
Search Results
4
records
(took 0.019 seconds)
